Clinical Research Studies of Atirmociclib in HR+/HER2- and/or HER2+ Breast Cancer
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.
For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.
Date RFP Issued: October 1, 2026
Geographic Scope: Australia, Brazil, Canada, China, France, Germany, Italy, Japan, Korea, Mexico, Spain, Taiwan, United Kingdom, United States
Clinical Area: Oncology - Breast
Research Concept Due Date: January 12, 2027
Specific Area of Interest: Pfizer is interested in supporting the following types of projects:
- Clinical translational research in post adjuvant CDK4/6i progression to illustrate genomic profiles and relevant treatment strategies.
- Clinical studies of atirmociclib in HER2+ disease to explore its potential clinical utility in selected patients. (eBC could be considered if sufficient data support the study in this potentially curative setting).
- Clinical studies of atirmociclib in HR+ mBC in combination with existing or emerging Standard of Care (SoC) (not overlapping with ongoing clinical trials and with commitment of novel drug supply from a third party).